Vanessa B Rocha

Prof. Dr. Vanessa B Rocha


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
MSMaria Antonieta Rios Scherrer
Maria Antonieta Rios Scherrer
VRVanessa B Rocha
Vanessa B Rocha
LGLucas Campos Garcia
Lucas Campos Garcia
Behçet's disease is a systemic vasculitis characterized by attacks of acute inflammation, which can affect almost every vascularized area of the body. There is a close correlation between the geographical distribution of HLA-B51 and its prevalence. In the etiopathogenesis there are indications of genetic susceptibility associated with environmental influence. Among the involved genes are those that encompass innate and adaptive immunities. Polymorphisms and epistatic interactions in several genes are described, as well as the presence of imbalance lineage between HLA-B51 and A (MICA). Herpes simplex and Streptococcus sanguinis may be important extrinsic factors. An increase of Th1 response and of IL-21 is observed. The production of IL-21 is positively related to Th17 cells and negatively to T-regs. The mucocutaneous manifestations are Behcet´s disease markers, and their earlier onset indicates a worse prognosis. Recurrent oral ulcers have varied sizes and arrangements, genital ulcers are recurrent, leaving scars, skin lesions are multivaried, and pathergy, although not so frequent, is important for the diagnosis. There are numerous attempts to validate indexes that can evaluate the disease activity and among them the Mucocutaneous Activity Index. This is a specific score that can help with therapeutic decisions and to reduce morbidity, but still lacks validation. The clinical manifestations of other organs are described as well as treatment options.

1 July 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
VRVanessa B Rocha
Vanessa B Rocha
ADA. Donati
A. Donati
LCL.A. Contin
L.A. Contin
PKP. Kakizaki
P. Kakizaki
CMC.J. Machado
C.J. Machado
MPM.C. Pires
M.C. Pires

8 December 2021 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
VRVanessa B Rocha
Vanessa B Rocha
CMCarla Jorge Machado
Carla Jorge Machado
LCLeticia Arsie Contin
Leticia Arsie Contin

1 December 2015 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
MSMaria Antonieta Rios Scherrer
Maria Antonieta Rios Scherrer
VRVanessa B Rocha
Vanessa B Rocha
AAAna Regina Coelho Andrade
Ana Regina Coelho Andrade
Methylisothiazolinone (MI) is a preservative found in cosmetic and industrial products. Contact dermatitis caused by either methylchloroisothiazolinone/methylisothiazolinone (MCI/MI or Kathon CG) or MI has shown increasing frequency. The latter is preferably detected through epicutaneous testing with aqueous MI 2000 ppm, which is not included in the Brazilian standard tray. We describe a series of 23 patients tested using it and our standard tray. A case with negative reaction to MCI/MI and positive to MI is emphasized.

1 November 2014 in Revista Brasileira de Reumatologia
Verified
Journal Article
Open access
MSMaria Antonieta Rios Scherrer
Maria Antonieta Rios Scherrer
LCLúcia Porto Fonseca de Castro
Lúcia Porto Fonseca de Castro
VRVanessa B Rocha
Vanessa B Rocha
LPLeonardo Pacheco
Leonardo Pacheco
Behçet's disease is a multisystemic disease consisting of a varying combination of ocular, mucocutaneous, neurologic, cardiovascular, gastrointestinal and other manifestations. Its diagnosis is based on clinical criteria, in which a positive pathergy test scores 1. A case series with 26 suspected patients is presented, and the skin pathergy test was performed in 23. The results were read in 48hours, and they were considered negative when without papule, and positive with a papule or pustule. Positive results were divided by papule size, and dermatoscopy was done to measure and observe its clinical aspects. After the readings, a biopsy was performed, with annotation of histopathological aspects. The test was negative in 2 (8.7%) and positive in 21 (91.3%) patients. The results and the literature review are presented.

30 March 2023 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
MSMaria Antonieta Rios Scherrer
Maria Antonieta Rios Scherrer
ÉAÉrica Possa Abreu
Érica Possa Abreu
VRVanessa B Rocha
Vanessa B Rocha
Neomycin is used in several over-the-counter pharmaceutical formulations in Brazil. In Europe and Canada, where it is not freely available, its sensitization frequency is lower than in the United States, where this does not occur. To present the frequency of sensitization to neomycin observed in a tertiary hospital and the pharmaceutical formulations sold in Brazil containing neomycin. Retrospective analysis of positive results to neomycin, obtained through patch tests performed in a tertiary hospital, from 2009 to 2018 and investigation of topical drugs and vaccines containing neomycin in Brazilian databases available on the internet. Among 1,162 patients, 71 (6%) had positive reactions to neomycin, 65% female and 35% male individuals, 46% were over 50 years old, and 24% had a personal history of atopy. The dermatitis lasted from four months to 20 years. Lesions were located in 69% of the patients on the upper limbs, in 55% they were on the lower limbs, and in 42% they were disseminated in more than 4 sites. Polysensitization was detected in 55% of cases. Of these, 28% were linked to sensitization to rubber allergens and 27% to potassium bichromate. A total of 158 topical presentations of neomycin were found: 79 ointments, 58 creams, 10 ophthalmic solutions, seven otological solutions, one oral solution, two nasal solutions, and one antiseptic powder, in addition to 11 types of vaccines. Retrospective study. Sensitization to neomycin occurred in 6% of the studied population, affecting more females aged over 50 years, with skin lesions located mainly on the upper and lower limbs, in the context of chronic contact dermatitis. Neomycin was found in 135 formulations, most of them available over the counter, as well as in 11 miscellaneous vaccines.